Insomnia News and Research

Latest Insomnia News and Research

Health Canada approves Valeant's NDA for Sublinox to treat insomnia

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada.

25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Insight into global incidence and prevalence of mild cognitive impairment

New research reported today in Paris at the Alzheimer's Association International Conference 2011 (AAIC 2011) offers insight on the global incidence and prevalence of mild cognitive impairment (MCI) – a condition involving problems with memory or another mental function severe enough to be noticeable to the affected person or to others but not serious enough to interfere with daily life.

19 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

Transcept decreases workforce following FDA news on Intermezzo NDA

Transcept Pharmaceuticals, Inc. announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S. Food and Drug Administration (FDA) that the resubmitted New Drug Application (NDA) for Intermezzo, the company's lead product candidate, cannot be approved in its present form.

16 Jul 2011

Transcept receives FDA Complete Response Letter for Intermezzo NDA

Transcept Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo.

15 Jul 2011

Scientists track public health trends through Twitter

Twitter allows millions of social media fans to comment in 140 characters or less on just about anything: an actor's outlandish behavior, an earthquake's tragic toll or the great taste of a grilled cheese sandwich.

8 Jul 2011

First ever clinical study using Brainwave Optimization technology to treat insomnia

Insomnia is the most prevalent sleep disorder, affecting up to 50 percent of the adult population in the United States on a weekly basis.

1 Jul 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.

22 Jun 2011

Rocking allows for better sleep – even in insomniac adults!

A new study shows that people tend to sleep faster and even achieve better quality sleep if they are gently swayed. The findings may explain why parents instinctively rock babies to sleep, and why we find it so easy to nod off when slumped in a rocking chair, they add

21 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Study finds link between energy drink consumption and substance use among musicians

Frequent use of energy drinks is associated with binge drinking, alcohol-related social problems and misuse of prescription drugs among musicians, according to researchers at the University at Buffalo's Research Institute on Addictions.

21 Jun 2011

Teenage soda consumption survey

According to a latest report from the Center for Disease Control (CDC), one fourth or 24% of students drank soda, down from 29% in 2009. The study was a part of the survey termed Analysis of the National Youth Physical Activity and Nutrition Study (NYPANS) conducted by CDC.

19 Jun 2011

Study shows increase in emergency department visits for drug-related suicide attempts among men

A new national study shows that from 2005 to 2009 there was a 55 percent increase in emergency department visits for drug related suicide attempts by men aged 21 to 34 -- from 19,024 visits in 2005 to 29,407 visits in 2009. In 2009, there were a total of 77,971 emergency department visits for drug-related suicide attempts among males of all ages.

18 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Marriage and sleep study: Lack of sleep affects wives, husbands stoic!

According to a new study by researchers at the University of Pittsburgh’s Sleep Medicine Institute, wives can be irritable with their husbands if they don't get a good night’s sleep.

15 Jun 2011

Insomnia News and Research

Latest Insomnia News and Research

Health Canada approves Valeant's NDA for Sublinox to treat insomnia

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Insight into global incidence and prevalence of mild cognitive impairment

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Transcept decreases workforce following FDA news on Intermezzo NDA

Transcept receives FDA Complete Response Letter for Intermezzo NDA

Scientists track public health trends through Twitter

First ever clinical study using Brainwave Optimization technology to treat insomnia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Rocking allows for better sleep – even in insomniac adults!

New anti-abuse formulation of painkiller Oxycodone

Study finds link between energy drink consumption and substance use among musicians

Teenage soda consumption survey

Study shows increase in emergency department visits for drug-related suicide attempts among men

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Marriage and sleep study: Lack of sleep affects wives, husbands stoic!

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Insomnia News and Research

Latest Insomnia News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in